Quantitative proteomics reveals pregnancy prognosis signature of polycystic ovary syndrome women based on machine learning

Figures & data

Table 1. Participant clinical characteristics of patients with PCOS and control.

	PCOS (n = 33)	Control (n = 7)	p
Age (year)	25.8 (3.1)	27.0 (2.9)	0.37
BMI (kg/m^2)	23.9 (21.1, 27.3)	20.8 (19.5, 22.0)	0.03
AMH (ng/mL)	9.0 (4.1)	1.8 (1.1)	<0.01
FSH (mIU/mL)	7.2 (5.9, 7.9)	5.3 (5.2, 6.3)	0.02
LH (mIU/mL)	11.8 (4.3)	5.3 (0.6)	<0.01
LH/FSH	1.8 (0.7)	1.0 (0.1)	<0.01
T (ng/dL)	42.1 (17.6)	24.7 (11.4)	0.02
FPG (mmol/L)	5.2 (0.5)	4.5 (0.4)	<0.01
FINS (mIU/mL)	16.2 (9.77, 25.84)	7.34 (6.49, 12)	0.02
HOMA-IR	3.89 (2.35, 6.29)	1.74 (1.29, 2.16)	0.01
ET (mm)	3.64 (2.86, 4.9)	9.59 (8.64, 10.41)	<0.01
Live birth (%)	20 (60.6)	7 (100)	0.04
Adverse gestation (%)	13 (39.4)	0 (0)

Note: BMi, body mass index; AMH, anti-mullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; T, testosterone; FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; ET, endometrial thickness.

p < 0.05 was considered statistically significant.

Table 2. Clinical data analysis in PCOS pregnancy loss and nonpregnancy loss.

	Nonpregnancy loss (n = 20)	Pregnancy loss (n = 13)	p
Age(year)			1.00
<30	18 (90%)	12 (92%)
>30	2 (10%)	1 (8%)
BMI (kg/m^2)	23.3 (3.4)	25.6 (4.0)	0.09
AMH (ng/mL)	9.4 (4.4)	8.2 (3.5)	0.43
FSH (mIU/mL)	6.7 (1.4)	7.0 (2.0)	0.64
LH (mIU/mL)	12.3 (3.5)	11.2 (5.3)	0.47
LH/FSH	1.9 (0.6)	1.6 (0.8)	0.33
T (ng/dL)	42.0 (11.8)	42.2 (24.5)	0.98
FPG (mmol/L)	5.2 (0.6)	5.2 (0.5)	0.81
FINS (mIU/mL)	11.8 (9.5, 25.5)	18.6 (15.6, 27.6)	0.10
HOMA-IR	2.8 (2.1, 6.0)	4.0 (3.3, 6.7)	0.10
ET (mm)	4.3 (1.6)	3.5 (1.1)	0.17
T3 (nmol/L)	1.8 (0.3)	1.9 (0.2)	0.45
T4 (nmol/L)	109.3 (18.2)	119.8 (15.6)	0.10
FT3 (pmol/L)	5.4 (0.5)	5.5 (0.4)	0.71
FT4 (pmol/L)	15.8 (2.0)	15.3 (1.5)	0.47
TSH (uIU/ml)	2.7 (1.2)	3.2 (1.2)	0.28
Thyroglobulin (ng/ml)	14.3 (8.5)	23.8 (21.2)	0.12
ATG-AB (U/ml)			1.00
<35	19 (95%)	12 (92%)
>35	1 (5%)	1 (8%)
TPO-AB (U/ml)			0.07
<35	12 (60%)	3 (23%)
>35	8 (40%)	10 (77%)
TC (mmol/L)	4.0 (0.8)	4.1 (0.6)	0.73
TG (mmol/L)	1.4 (0.9)	1.6 (0.9)	0.1
HDL (mmol/L)	1.3 (0.3)	1.3 (0.3)	0.82
LDL (mmol/L)	2.6 (0.7)	2.7 (0.7)	0.71
HCY (umol/L)	12.0 (9.5, 15.5)	11.0 (8.0, 14.0)	0.30
VD3 (ng/L)	10.0 (4.0)	12.3 (5.1)	0.16
D2 polyme (mg/L)	0.1 (0.1, 0.2)	0.2 (0.1, 0.4)	0.75
CA125(U/ml)	12.9 (11.0, 16.5)	12.9 (10.5, 14.7)	0.15

Note: T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; ATG-AB, antithyroglobulin antibody; TPO-AB, thyroid peroxidase antibody; TC, cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low density Lipoprotein; HCY, homocysteine.

p < 0.05 was considered statistically significant.

Figure 1. Establishment and Evaluation of the Risk Prognostic Model: A) Nomogram to estimate the probability of pregnancy outcome of P COS use feature proteins; B) Forest plots of two feature proteins identified by multivariate Coxregression analysis; C-D) Expression of two feature proteins in pregnancy loss and NO-pregnancy loss; E) Survival analysis between high and low-risk groups; F) The ROC curve use to evaluation of the risk model. G) Decision curve analysis for the Risk model; H-I) The calibration curve of nomogram.

Figure 2. The relationship between feature proteins and clinical data.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession numbers can be found below: The mass spectrometry proteomics data have been deposited to the ProteomeXchange consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository with the dataset identifier PXD032383.